leisure time -WSS

leisure time

author：Wikipedia 2025-08-27 22:46:27 - browse：6645

Adobe

The medical device industry is split on whether a proposed new Medicare reimbursement pathway will do anything to soothe their insurance coverage woes.

Device makers have long complained that the unclear, rocky road to payment kills innovative companies. So they were thrilled when the Trump administration proposed a rule that would have guaranteed four years of Medicare coverage of approved devices deemed “breakthroughs” by the Food and Drug Administration. They hoped private payers would follow suit. But in 2021, under a new administration and a push for more device scrutiny, the Centers for Medicare and Medicaid pulled back on the idea, promising a replacement that would streamline coverage for innovative devices while ensuring safe, high-quality care.

The pathway put forth last week, called Transitional Coverage for Emerging Technologies (TCET), is only a notice, not yet a rule that would grant CMS new powers. The program applies solely to devices that have earned a place in the FDA’s breakthrough device program, which was established to identify devices that the agency believed could provide “more effective” treatment or diagnosis of serious conditions than the current standard of care. But because those devices can be brought to market with less certainty in their benefits and risks than other products, experts said, the idea of automatic reimbursement was dicey.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

focus

WSS

At ASCO, AstraZeneca reports strong data for breast cancer drug

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

US ambassador visits Wall Street Journal reporter detained in Russia on charges of espionage

Let's speed up science by embracing open access publishing

10 states plan to sue EPA over standards for residential wood

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

Wikipedia

leisure time

entertainment

Virginia high school admissions case could be legal follow

3 killed, 8 injured in late

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

3 killed, 8 injured in late

Medical leaders decry Supreme Court decision on affirmative action

The Democratic Party promised to overhaul its primaries. Doing that has been anything but simple

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

July 4th fireworks can be stressful for dogs. These 6 tips can keep them calm and safe

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

NASA releases new images of 'fingerprint

explore

The Pandemic Treaty must support building strong health systems

Churchill Downs extends trainer Bob Baffert's ban through 2024

Woman returns to dialysis after doctors remove transplanted pig kidney

Noem? Reynolds? A very early look at the Republican 'veepstakes'

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

Innovation in antibiotics is ailing. 'Brain drain' may kill it

leisure time

knowledge

focus

knowledge